OBJECTIVE: To investigate the effectiveness and safety of intravitreal injection of conbercept (IVC) as the initial treatment for exudative circumscribed choroidal haemangioma (CCH). METHODS: Forty-two eyes of 42 patients received three monthly IVC (0.5mg/0.05ml) as the initial treatment. Three months later, patients were assessed for further treatment including observation, re-injection of conbercept, laser photocoagulation (lesion was 3000μm away from macular fovea) or photodynamic therapy (PDT, lesion under macular fovea). Anatomical and functional responses including best corrected visual acuity (BCVA), central foveal thickness (CFT), and tumor size were analyzed. RESULTS: 23 patients (54.76%) were sensitive to the monotherapy of IVC. 14 patients (33.33%) were insensitive to IVC and underwent rescue laser photocoagulation, 5 patients (11.90%) underwent rescue PDT due to insensitiveness to IVC treatment at Month 3. For subgroup analysis, although no statistical difference was found for BCVA at any follow-up time-point compared with the baseline, an increasing tendency of BCVA was found in IVC group (P>0.05). The mean CFT decreased significantly from 427.13±214.74μm at the baseline to 259.83±61.68μm at Month 6 in the IVC group (P<0.05). No influence was found on tumor size in IVC group. CONCLUSION: IVC as the initial treatment might be a treatment option for exudative CCH.
OBJECTIVE: To investigate the effectiveness and safety of intravitreal injection of conbercept (IVC) as the initial treatment for exudative circumscribed choroidal haemangioma (CCH). METHODS: Forty-two eyes of 42 patients received three monthly IVC (0.5mg/0.05ml) as the initial treatment. Three months later, patients were assessed for further treatment including observation, re-injection of conbercept, laser photocoagulation (lesion was 3000μm away from macular fovea) or photodynamic therapy (PDT, lesion under macular fovea). Anatomical and functional responses including best corrected visual acuity (BCVA), central foveal thickness (CFT), and tumor size were analyzed. RESULTS: 23 patients (54.76%) were sensitive to the monotherapy of IVC. 14 patients (33.33%) were insensitive to IVC and underwent rescue laser photocoagulation, 5 patients (11.90%) underwent rescue PDT due to insensitiveness to IVC treatment at Month 3. For subgroup analysis, although no statistical difference was found for BCVA at any follow-up time-point compared with the baseline, an increasing tendency of BCVA was found in IVC group (P>0.05). The mean CFT decreased significantly from 427.13±214.74μm at the baseline to 259.83±61.68μm at Month 6 in the IVC group (P<0.05). No influence was found on tumor size in IVC group. CONCLUSION: IVC as the initial treatment might be a treatment option for exudative CCH.